Alder Biopharmaceuticals Inc (ALDR) : Partner Fund Management scooped up 1,652,617 additional shares in Alder Biopharmaceuticals Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 3,542,647 shares of Alder Biopharmaceuticals Inc which is valued at $110,282,601.Alder Biopharmaceuticals Inc makes up approximately 3.76% of Partner Fund Management’s portfolio.
Other Hedge Funds, Including , Hbk Investments L P added ALDR to its portfolio by purchasing 11,500 company shares during the most recent quarter which is valued at $357,995. Alder Biopharmaceuticals Inc makes up approx 0.01% of Hbk Investments L P’s portfolio.Blackrock Group Ltd reduced its stake in ALDR by selling 11,783 shares or 16.71% in the most recent quarter. The Hedge Fund company now holds 58,713 shares of ALDR which is valued at $1,827,736.Pioneer Investment Management Inc boosted its stake in ALDR in the latest quarter, The investment management firm added 402,270 additional shares and now holds a total of 824,988 shares of Alder Biopharmaceuticals Inc which is valued at $25,681,876. Alder Biopharmaceuticals Inc makes up approx 0.09% of Pioneer Investment Management Inc’s portfolio.California Public Employees Retirement System reduced its stake in ALDR by selling 2,400 shares or 3.13% in the most recent quarter. The Hedge Fund company now holds 74,200 shares of ALDR which is valued at $2,326,912. Gilder Gagnon Howe Co added ALDR to its portfolio by purchasing 3,193 company shares during the most recent quarter which is valued at $100,132.
Alder Biopharmaceuticals Inc closed down -0.43 points or -1.30% at $32.54 with 3,97,238 shares getting traded on Thursday. Post opening the session at $32.96, the shares hit an intraday low of $32.045 and an intraday high of $33.23 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, Alder Biopharmaceuticals Inc reported $-0.76 EPS for the quarter, missing the analyst consensus estimate by $ -0.04 based on the information available during the earnings call on Apr 28, 2016. Analyst had a consensus of $-0.72.Analysts expectations of $ .14.During the same quarter in the previous year, the company posted $-0.40 EPS.
Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company discovers develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy as well as speed of onset and durability of therapeutic response. The Company’s pipeline includes ALD403 Clazakizumab and ALD1613. ALD403 is the Company’s monoclonal antibody targeted to calcitonin gene-related peptide (CGRP) for migraine prevention. Clazakizumab is a monoclonal antibody that inhibits the pro-inflammatory cytokine interleukin-6 (IL-6) and is in development for both rheumatoid arthritis (RA) and psoriatic arthritis (PsA). ALD1613 is a monoclonal antibody that inhibits Adrenocorticotropic Hormone (ACTH) and is being developed for the treatment of Cushing’s disease.